Literature DB >> 2821940

Pharmacologic evaluation and structure activity relationships of a series of hemicholinium-3 (HC-3) analogs.

B Bhattacharyya1, M D Sokoll, J G Cannon, J P Long.   

Abstract

Piperidine derivatives of hemicholinium-3 were synthesized, which included the following spacing groups between cationic heads: trans-trans-bicyclohexyl, phenanthrene, naphthalene, and biphenyl. Relatively minor structural alterations in these series of compounds resulted in several different types of pharmacological actions related to cholinergic transmission. Structural requirements of the compounds are discussed and include internitrogen distance, structural planarity, spacing groups, and positional isomerism of the quaternary cationic heads. Selected quaternary piperidine derivatives with 14 A inter-atomic distance between the cationic heads exhibit potent HC-3 like activity which is enhanced if a molecule has a nonpolar space filling group (4-methyl piperidine) approximately 3.7 A from the corresponding quaternary cationic head. With selected piperidine ring substitutions, active tertiary amines were also identified. Compounds containing C = O in the spacing moiety were active inhibitors of cholinesterase with some derivatives being nearly as active as physostigmine. When the C = O moiety was reduced to -CH2 and a 2 or 3-CH3 piperidine ring was present, potent non-depolarizing, short acting neuromuscular blocking agents were obtained.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821940

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  2 in total

1.  Structure-activity relationship studies of hemicholinium (HC-3) congeners.

Authors:  J G Cannon; T M Lee; Y Chang; A M Nyanda; B Bhattacharyya; J R Flynn; T Chatterjee; R K Bhatnagar; J P Long
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

Review 2.  Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Authors:  Sean P Arlauckas; Anatoliy V Popov; E James Delikatny
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.